Neuberger Berman Group LLC Has $5.68 Million Stock Holdings in Humana Inc. $HUM

Key Points

• Neuberger Berman Group LLC has reduced its stake in Humana Inc. (NYSE:HUM) by 85.2%, selling 123,505 shares and now holding only 21,475 shares worth approximately $5.68 million.
• Deutsche Bank AG increased its stake in Humana by 18.2% during the last quarter, making it one of several hedge funds adjusting their holdings in the company.
• Analysts' ratings for Humana have shifted, with Wall Street Zen downgrading the stock from "buy" to "hold" and a consensus target price now at $281.45.

Neuberger Berman Group LLC lowered its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 85.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,475 shares of the insurance provider's stock after selling 123,505 shares during the quarter. Neuberger Berman Group LLC's holdings in Humana were worth $5,682,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in HUM. Vanguard Group Inc. increased its holdings in shares of Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after purchasing an additional 1,143,662 shares during the period. GAMMA Investing LLC increased its stake in Humana by 40,881.1% during the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock worth $2,066,790,000 after acquiring an additional 779,193 shares during the last quarter. Southpoint Capital Advisors LP purchased a new position in shares of Humana during the fourth quarter worth $190,282,000. Nuveen LLC purchased a new position in Humana in the first quarter valued at $171,220,000. Finally, 8 Knots Management LLC purchased a new stake in Humana during the 4th quarter worth about $145,258,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HUM. Robert W. Baird dropped their price target on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Oppenheimer upped their target price on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Wall Street Zen downgraded Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Morgan Stanley lowered their price target on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Finally, Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price for the company in a research note on Thursday, May 1st. Seven analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $281.43.

Humana Trading Up 0.4%

NYSE HUM traded up $1.08 on Tuesday, hitting $288.27. 867,078 shares of the stock were exchanged, compared to its average volume of 1,728,172. The company's 50-day moving average price is $243.80 and its two-hundred day moving average price is $253.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $382.72. The company has a market capitalization of $34.67 billion, a price-to-earnings ratio of 22.10, a P/E/G ratio of 1.68 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. Research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.